Business · Markets · StrategySupport
CII — Corporate Insider Inc.CII
Subscribe
S&P 5006,412.08+0.62%
NASDAQ21,884.30+1.04%
DOW44,910.55-0.18%
10-YR4.13%-0.03
BRENT$71.44+0.91%
BTC$96,120-2.11%
S&P 5006,412.08+0.62%
NASDAQ21,884.30+1.04%
DOW44,910.55-0.18%
10-YR4.13%-0.03
BRENT$71.44+0.91%
BTC$96,120-2.11%

Deals

AstraZeneca Puts $2 Billion Into Summit Therapeutics Through Convertible Preferred Shares

The investment converts at an implied $18.36 a share and comes with a clinical collaboration pairing Summit's ivonescimab with AstraZeneca cancer medicines.

AF

By Anna Ferreira

Sep 29, 2026 · 5 min read

AstraZeneca is investing $2.0 billion in Summit Therapeutics through convertible preferred shares, the companies announced Monday. Summit filed a Form 8-K on Tuesday covering the unregistered equity sale, an amendment to its charter and related matters.

Discussion (0)

Sign in to join the discussion.

Loading comments…

AF

Anna Ferreira

Senior Correspondent, Corporate Strategy

Anna Ferreira writes for Corporate Insider Inc.

CII Briefing

The 7am memo for people who run things

One email. The deals, the numbers and the decisions that will be discussed in your Monday meeting.

Free. Unsubscribe any time. We never share your address.